 PRINCETON, NJ ACCESSWIRE March 22, 2021 Sonnet BioTherapeutics Holdings, Inc. NASDAQ:SONN Sonnet or the Company, a biopharmaceutical company developing innovative targeted biologic drugs, announced today the appointment of Richard Kenney, M.D. as Chief Medical Officer and Manuel Dafonseca, as Head of Clinical Operations, effective March 22, 2021. 